MARKET

ANIK

ANIK

Anika
NASDAQ

Real-time Quotes | Nasdaq Last Sale

35.77
-0.57
-1.57%
After Hours: 35.77 0 0.00% 16:00 08/14 EDT
OPEN
36.20
PREV CLOSE
36.34
HIGH
36.24
LOW
35.33
VOLUME
128.10K
TURNOVER
--
52 WEEK HIGH
75.72
52 WEEK LOW
22.01
MARKET CAP
508.20M
P/E (TTM)
46.11
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ANIK stock price target is 51.00 with a high estimate of 51.00 and a low estimate of 51.00.

EPS

ANIK News

More
Anika Appoints Michael Levitz as Chief Financial Officer
Seasoned financial executive brings broad medical device industry experience and track record of value creationBEDFORD, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and r
GlobeNewswire · 08/05 20:09
ANIK or ALKS: Which Is the Better Value Stock Right Now?
ANIK vs. ALKS: Which Stock Is the Better Value Option?
Zacks · 08/05 15:40
Did Hedge Funds Make The Right Call On Anika Therapeutics, Inc. (ANIK) ?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds
Insider Monkey · 08/04 15:00
Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/02 17:54
Anika Therapeutics: After A Stormy Period, Orthopedic Specialist Looks Set Fair
Seeking Alpha · 07/31 04:00
Anika Therapeutics Inc (ANIK) Q2 2020 Earnings Call Transcript
With me today on the call is Dr. Cheryl Blanchard, President and Chief Executive Officer; and Sylvia Cheung, Chief Financial Officer of Anika. During today's call, Cheryl and Sylvia will review Anika's second quarter 2020 financial results and key business hi
Motley Fool · 07/30 23:30
Anika Therapeutics (ANIK) Q2 Earnings and Revenues Surpass Estimates
Anika (ANIK) delivered earnings and revenue surprises of 142.86% and 83.37%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 23:10
Anika Therapeutics Q2 EPS $(0.54) Misses $(0.24) Estimate, Sales $30.70M Beat $20.37M Estimate
Anika Therapeutics (NASDAQ:ANIK) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.24) by 125 percent. This is a 180.6 percent decrease over earnings of $0.67 per share
Benzinga · 07/30 20:18

Industry

Pharmaceuticals
-0.37%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Symbol
Price
%Change

About ANIK

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
More

Webull offers kinds of Anika Therapeutics Inc stock information, including NASDAQ:ANIK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIK stock methods without spending real money on the virtual paper trading platform.